KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses: 2013-2023

Historic Other Accumulated Expenses for Supernus Pharmaceuticals (SUPN) over the last 11 years, with Dec 2023 value amounting to $4.3 million.

  • Supernus Pharmaceuticals' Other Accumulated Expenses was N/A to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 million, marking a year-over-year change of. This contributed to the annual value of $4.3 million for FY2023, which is 74.60% down from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Other Accumulated Expenses of $4.3 million as of FY2023, which was down 74.60% from $16.9 million recorded in FY2022.
  • Supernus Pharmaceuticals' Other Accumulated Expenses' 5-year high stood at $20.1 million during FY2021, with a 5-year trough of $3.2 million in FY2019.
  • In the last 3 years, Supernus Pharmaceuticals' Other Accumulated Expenses had a median value of $16.9 million in 2022 and averaged $13.8 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Other Accumulated Expenses surged by 179.96% in 2020 and then crashed by 74.60% in 2023.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Other Accumulated Expenses stood at $3.2 million in 2019, then skyrocketed by 179.96% to $9.1 million in 2020, then soared by 121.67% to $20.1 million in 2021, then declined by 16.24% to $16.9 million in 2022, then crashed by 74.60% to $4.3 million in 2023.